Logo

BSX

Boston Scientific Corporation

BSX

Boston Scientific Corporation • NYSE
$101.58 ▲ 0.61% (+0.62)
Market Cap $150.59 B
52w High $109.50
52w Low $85.98
Dividend Yield 0%
P/E 54.32
Volume 2.78M
Outstanding Shares 1.48B

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $5.065B ▲ $2.492B ▼ $755M ▼ 14.906% ▼ $0.51 ▼ $1.026B ▼
Q2-2025 $5.061B ▲ $2.605B ▲ $793M ▲ 15.669% ▲ $0.54 ▲ $1.367B ▲
Q1-2025 $4.663B ▲ $2.054B ▼ $674M ▲ 14.454% ▲ $0.456 ▲ $1.217B ▲
Q4-2024 $4.561B ▲ $2.082B ▲ $566M ▲ 12.41% ▲ $0.384 ▲ $1.071B ▲
Q3-2024 $4.209B $1.974B $469M 11.143% $0.319 $1.058B

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $534M ▼ $41.559B ▲ $18.906B ▲ $22.418B ▲
Q1-2025 $725M ▲ $40.14B ▲ $17.694B ▲ $22.212B ▲
Q4-2024 $414M ▼ $39.395B ▲ $17.392B ▲ $21.77B ▲
Q3-2024 $2.502B ▼ $38.078B ▲ $17.122B ▲ $20.708B ▲
Q2-2024 $2.913B $37.108B $16.498B $20.371B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $795M ▲ $1.286B ▲ $-1.126B ▼ $-340M ▼ $-178M ▼ $1.096B ▲
Q1-2025 $672M ▲ $541M ▼ $-500M ▲ $233M ▲ $313M ▲ $354M ▼
Q4-2024 $562M ▼ $1.456B ▲ $-3.704B ▼ $214M ▲ $-2.043B ▼ $1.163B ▲
Q3-2024 $700M ▲ $1.002B ▲ $-1.427B ▼ $7M ▼ $-413M ▼ $698M ▲
Q2-2024 $324M $813M $-271M $24M $566M $658M

Revenue by Products

Product Q3-2024Q4-2024Q1-2025Q2-2025
Cardiovascular
Cardiovascular
 $2.73Bn ▲$2.94Bn ▲$3.08Bn ▲$3.35Bn ▲
MedSurg
MedSurg
 $1.48Bn ▲$1.62Bn ▲$1.58Bn ▼$1.72Bn ▲

Five-Year Company Overview

Income Statement

Income Statement Boston Scientific’s revenue has grown steadily over the past five years, showing healthy demand across its device portfolio. Profitability has improved meaningfully, moving from a marginal position during the pandemic period to solid, consistent earnings more recently. Margins have generally trended upward, indicating better scale, improved product mix, and operating discipline. There was a bumpier year in the middle of the period, likely tied to one‑off items or integration costs, but the overall direction of earnings is clearly positive.

Balance Sheet

Balance Sheet The balance sheet shows a business that has been expanding: total assets and shareholders’ equity have grown at a good pace, reflecting retained profits and investment in the franchise. Debt has also increased, which suggests the company is using borrowing to help fund acquisitions, R&D, and capacity. Cash on hand is relatively modest compared with total debt, so the company is leaning more on ongoing cash generation than on large cash reserves. Overall, it looks like a growth‑oriented balance sheet with manageable, but not trivial, leverage that investors would want to monitor over time.

Cash Flow

Cash Flow Boston Scientific consistently generates solid cash from its operations, and those cash flows have strengthened over the five‑year period. After funding capital spending, the company has produced healthy and rising free cash flow, indicating it can invest in growth while still having cash left for debt service and strategic moves. Capital expenditures have increased gradually but remain well covered by operating cash, which is a good sign of sustainable reinvestment rather than cash strain. This cash profile supports the company’s ability to keep funding innovation and acquisitions without overstretching its finances.

Competitive Edge

Competitive Edge The company holds a strong position in the global medical device market, especially in cardiology, electrophysiology, and other minimally invasive specialties. Its large, diversified product portfolio reduces dependence on any single technology or procedure, which can smooth performance as clinical practices evolve. A wide patent estate, deep physician relationships, and global distribution create meaningful barriers to entry. At the same time, Boston Scientific operates in highly competitive, innovation‑driven markets against other major device makers, so it must continually execute well just to maintain share.

Innovation and R&D

Innovation and R&D Innovation is clearly at the center of Boston Scientific’s strategy. Flagship platforms like the WATCHMAN device for stroke prevention and the FARAPULSE pulsed field ablation system in atrial fibrillation highlight its focus on high‑impact, minimally invasive solutions. The company invests heavily in R&D, runs extensive clinical programs, and supplements internal development with targeted acquisitions, which together support a robust pipeline. Strong training and education programs for physicians, plus ongoing upgrades to stents, rhythm management devices, and remote monitoring tools, help reinforce both adoption and loyalty over time.

Summary

Boston Scientific combines steady top‑line growth, improving profitability, and strong cash generation with a balance sheet that reflects an active, growth‑driven strategy. Its competitive strength rests on a broad, clinically important product portfolio, strong intellectual property, and deep relationships with specialists around the world. The company’s emphasis on minimally invasive technologies and next‑generation cardiac therapies positions it well for structural healthcare trends such as aging populations and pressure to reduce hospital stays. Key watchpoints include ongoing competitive pressure, regulatory and reimbursement changes, and the need to keep managing leverage prudently as it continues to invest in innovation and acquisitions.

NEWS

November 3, 2025 · 8:00 AM UTC

Boston Scientific announces upcoming investor conference schedule

Read more

October 22, 2025 · 6:30 AM UTC

Boston Scientific announces results for third quarter 2025

Read more

October 17, 2025 · 7:00 AM UTC

Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.

Read more

September 2, 2025 · 8:00 AM UTC

Boston Scientific announces 2025 Investor Day meeting and conference call discussing third quarter 2025 results

Read more